Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the recipient of a large growth in short interest in the month of June. As of June 15th, there was short interest totaling 410,154 shares, a growth of 186.5% from the May 31st total of 143,168 shares. Based on an average daily volume of 108,694 shares, the short-interest ratio is currently 3.8 days. Approximately 4.9% of the shares of the company are sold short.
Cocrystal Pharma Price Performance
Shares of NASDAQ:COCP traded up $0.02 during mid-day trading on Tuesday, reaching $1.05. 39,496 shares of the company traded hands, compared to its average volume of 1,275,641. The company’s 50 day moving average price is $1.18 and its 200-day moving average price is $1.11. The firm has a market cap of $14.48 million, a PE ratio of -1.44 and a beta of 1.42. Cocrystal Pharma has a 52 week low of $0.86 and a 52 week high of $2.67.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last released its earnings results on Friday, May 15th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.23 million. On average, research analysts predict that Cocrystal Pharma will post -0.69 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on COCP
Hedge Funds Weigh In On Cocrystal Pharma
A hedge fund recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC bought a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma at the end of the most recent quarter. Hedge funds and other institutional investors own 6.72% of the company’s stock.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.
The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.
Featured Articles
- Five stocks we like better than Cocrystal Pharma
- Rocket Lab Defies Gravity With $8B Buyout
- Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks
- The Quantum Bubble Is Real Enough to Take Seriously
- Why Wall Street Still Sees Massive Upside for AeroVironment Stock
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
